Assessing minimal residual disease in colorectal cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the potential of circulating tumor DNA (ctDNA) and other tumor-related molecules in the blood to predict the recurrence or spread of colorectal cancer. It aims to monitor cancer-specific DNA, RNA, and proteomic changes from plasma samples collected at various stages of treatment and follow-up. The study will analyze these alterations to improve detection of cancer recurrences post-curative therapies and assess their correlation with patient outcomes such as disease-free survival and overall survival.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years.
2. Histological/cytological confirmation of colorectal adenocarcinoma.
3. Patients with any stage colorectal adenocarcinoma deemed potentially eligible for curative intent treatment. Patients with stages II-IV colorectal cancer post-R0 resection may also be enrolled onto the protocol any time before or up to 3 months post-surgery and prior to initiating adjuvant therapy.
4. Ability to understand and the willingness to sign a written informed consent document.
5. Willing to pursue standard of care surveillance post completion of curative therapies.
6. Willing to provide blood samples for correlative research.

Exclusion Criteria:

1. Known active malignancies other than colorectal adenocarcinoma that may interfere with detection and / or interpretation of circulating plasma markers. Patients with known clonal hematopoiesis of indeterminate potential are eligible.
2. Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

Where it's running

• M D Anderson Cancer Center
  Houston, Texas, United States Recruiting
• Banner - MD Anderson Cancer Center
  Gilbert, Arizona, United States Terminated
• Baptist- MD Anderson Cancer Center
  Jacksonville, Florida, United States Terminated
• The Queen's Medical Center
  Honolulu, Hawaii, United States Terminated
• St. Luke's Cancer Institute
  Boise, Idaho, United States Terminated
• Cooper Hospital UNIV MED CTR.
  Camden, New Jersey, United States Terminated

Study contacts

• Principal investigator: Arvind Dasari — M.D. Anderson Cancer Center
• Study coordinator: Arvind Dasari
• Email: adasari@mdanderson.org
• Phone: (713) 792-2828

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining trifluridine/tipiracil with talazoparib for advanced colorectal or gastroesophageal cancer

  This study is testing a new combination of two cancer drugs to see if they can safely help people with advanced colorectal or gastroesophageal cancer.

  Recruiting Phase 1 Roswell Park Cancer Institute · Buffalo, New York · NCT04511039

• Family genetics: who shares test results with relatives

  This study tests whether letting patients share genetic results with their relatives is as good as doctors sharing the results to help first-degree relatives get genetic testing for hereditary cancer risk.

  Recruiting at 362 sites Alliance for Clinical Trials in Oncology · Birmingham, Alabama and 364 other locations · NCT07143487

• Avapritinib for treating advanced solid tumors with specific mutations

  This study is testing if a new drug called avapritinib can help people with advanced solid tumors that have specific mutations feel better and live longer after other treatments haven't worked.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT04771520

• Combining botensilimab and balstilimab after standard treatment for colorectal cancer

  This phase 2 trial tests whether giving botensilimab and balstilimab after standard therapy can clear detectable ctDNA in adults with stage II/III colorectal cancer.

  Recruiting at 2 sites Phase 2 National Cancer Institute (NCI) · New Orleans, Louisiana and 1 other locations · NCT07551596

• Zanidatamab given before surgery for HER2-positive colon or rectal cancer

  This tests whether giving zanidatamab before surgery helps adults with HER2-positive, RAS‑wildtype colon or rectal cancer who are planned for curative treatment.

  Recruiting at 4 sites Phase 2 Emory University · Atlanta, Georgia and 3 other locations · NCT07405476

• Helping colorectal cancer survivors keep up with post-surgery surveillance

  This project tests whether patient navigation services, an interactive web program called Current Together After Cancer (CTAC), or both help people with stage I–III colorectal cancer keep up with recommended post-surgery surveillance.

  Recruiting at 2 sites Fred Hutchinson Cancer Center · Seattle, Washington and 1 other locations · NCT06995924

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.